Opioid-induced Constipation 
The MD Magazine Opioid-induced Constipation condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Sponsored

Synergy Pharmaceuticals Submits NDA for IBS-C Drug Plecanatide
Pharma submits sNDA for IBS-C drug plecanatide.
The FDA today approved constipation remedy plecanatide.
Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.
There are many challenges that confront pain specialists on a daily basis. Despite those challenges, seeing their patients recover and live a better quality of life is reward enough to keep them optimistic for the future of the field.
Injectable medications are being used for everything from chronic pain to cancer related pain. While doctors are working to help their patients manage their symptoms they are also keeping a close eye on potential abuse and illegal activity with the medication.
Ketamine is not a new tool in the arsenal of pain medication but doctors are finding new ways to use it in order to provide relief for patients. As an infusion ketamine is being used to treat chronic pain syndromes.
In an effort to avoid prescribing opioids except in cases where they are needed doctors are finding new ways to provide relief for their patients. This can include newly developed implantable medications which can help reduce pain and increase quality of life.
When opioids first hit the market they were specifically promoted for their non-addictive traits. Over the past few decades that has been disproven as doctors look for the best way to treat patients and avoid the risk of unwanted addiction and other issues.
As the main treatment in pain medication opioids are widely prescribed for patients who need them. Balancing that with the risk of addiction and abuse is something providers deal with on a regular basis.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$